Progress in treatment for idiopathic pulmonary fibrosis
LIU Chuan-mei1, CAI Hou-rong1,2*
1 Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, China;2 Department of Respiration Medicine, Drum
Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Abstract：Objective : To summarize the progress of drugs for idiopathic pulmonary fibrosis(IPF) treatment. Methods : The data of drugs in the treatment of IPF domestically and internationally in recent years was collected and analyzed. Results and conclusion : Drugs for IPF including corticosteroid combined acetylcysteine and azathioprine, acetylcystenine monotherapy and Anticoagulation were all denined. Pirfenidone and nintedanib can slow down the decline i n lung function, but can not stop disease progression.
[1] Raghu G，Collard H R，Egan J J，et a1．An official ATS / ERS / JRS / ALAT statement：idiopathic pulmonary fibrosis：evidence-based guidelines for diagnosis and management[J]．Am J Respir Crit Care Med, 2011, 183(6)：788-824．
[2] Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature[J]. Eur Respir Rev, 2012, 21(126):355-361.
[3] Richeldi L, Davies H R, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis[J/CD]. Cochrane Database Syst Rev, 2003(3):CD002880.
[4] Davies H R, Richeldi L, Walters E H. Immunomodulatory agents for idiopathic pulmonary fibrosis[J/CD]. Cochrane Database Syst Rev, 2003(3):CD003134.
[5] 蔡后荣. 2011特发性肺纤维化诊断及治疗指南解读[J].中华呼吸与危重监护杂志, 2011, 10(4):313-316.
[6] 黄慧，李红杰，徐作军.特发性肺纤维化的药物治疗[J].临床药物治疗杂志, 2011, 9(6):40-44.
[7] Demedts M, Behr J, Buhl R, el a1．High-dose acetylcysteine in idiopathic pulmonary fibrosis[J]．N Engl J Med, 2005, 353(21):2229-2242．
[8] Raghu G, Anstrom K J, King T E Jr, et a1. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis[J]．N Engl J Med, 2012, 366(21):1968-1977.
[9] Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez F J, de Andrade J A,et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis[J].N Engl J Med, 2014, 370(22):2093-2101.
[10] Noth I, Anstrom K J, Calvert S B, et al. A Placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2012, 186(1):88–95.
[11] Raqhu G, Johnson W C, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent，pirfenidone: results of a prospective，open-label phase II study[J].Am J Respir Crit Care Med, 1999, 159(4 Pt1):1061-1069．
[12] Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind,placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2005, 171(9):1040-1047.
[13] Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2010, 35(4):821-829.
[14] Noble P W, Albera C, Bradford W Z, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials [J]. Lancet, 2011, 377(9779):1760-1769.
[15] King T E, Bradford W Z, Castro-Bernardini S, et al. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22):2083-2092.
[16] Valeyre D, Albera C, Bradford W Z, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis[J].Respirology, 2014, 19(5):740-747.
[17] Richeldi L,Costabel U, Selman M, et al. Efficacy of a tyrosine kinasei nhibitor in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2011, 365(12):1079-1087.
[18] Richeldi L, du Bois R M, Raqhu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonaryfibrosis [J].N Engl J Med, 2014, 370(22):2071-2082.
2015, Vol. 13 
